## Supplementary Figure 4



Supplementary Figure 4. Addition of myr-*p110a* elevates the levels of PI3K signaling activation in a copy number-dependent manner. (A) Western blot analysis of p110a, p-AKT, AKT, and GFP with normal mammary tissue and mammary tumors from  $p53^{fl/fl}$ ; *Kras*<sup>G12D</sup>,  $p53^{fl/fl}$ ; *Kras*<sup>G12D</sup>; myr-*p110a*<sup>wt/fl</sup>, and  $p53^{fl/fl}$ ; *Kras*<sup>G12D</sup>; myr-*p110a*<sup>fl/fl</sup> mice. (B) The graphs of Western blot signals of p110a, p-AKT, and p-AKT/AKT ratio shown in (A). (C) Western blot

analysis of p110 $\alpha$ , p-AKT, AKT, and GFP with normal mammary tissue and mammary tumors from *p53<sup>fl/fl</sup>*;myr-*p110\alpha^{wt/fl}* and *p53<sup>fl/fl</sup>*;myr-*p110\alpha^{fl/fl}* mice. (D) The graphs of Western blot signals of p110 $\alpha$ , p-AKT, and p-AKT/AKT ratio shown in (C). The Western blot signals quantified and normalized with respect to  $\beta$ -Actin protein expression. Mean fold increase compared with normal mammary tissue lysates from a non-Cre harboring age-matched female, was calculated after normalization. Error bars are presented as the mean ± SEM. Two-tailed unpaired Student's *t*-test was used for statistical analysis. \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001. Expression of myr-*p110\alpha* was confirmed by the detection of GFP in mammary tumors. Data are representative of 3 independent experiments with biological and technical replicates.